WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Wednesday that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Turkish health regulator TITCK.
This marks the first GMP inspection conducted by Turkey's TITCK at WuXi Biologics. During the five-day onsite inspection of two monoclonal antibody biologics produced by WuXi Biologics for its clients, the three manufacturing facilities successfully passed TITCK's comprehensive assessment. All these facilities have previously received approval from other major regulatory authorities for the development of multiple biologic therapeutics.
As of the end of June 2025, Wuxi has successfully passed 44 regulatory inspections, including 22 conducted by the FDA and the EMA.
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering